Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × NSCLC × aflutinib × Clear all

Phase

Status

Unknown 2 Recruiting 2 Active not recruiting 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

NSCLC 1 Advanced NSCLC Patients With T790M 1 Advanced NSCLC 1

Interventions

Pemetrexed 3 Carboplatin 3 HM781-36B 2 Gemcitabine 2 pembrolizumab 1 osimertinib 1 aumolertinib 1 aflutinib 1 Taxes 1 Paclitaxel 1 Erlotinib Hydrochloride 1 Clinical Trials, Phase I as Topic 1 Cisplatin 1 Bortezomib 1 BID protein, human 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02973763 2025-04-03

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Allist Pharmaceuticals, Inc.

Phase 1 Terminated

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡